Life Whisperer AI will take center stage with four oral presentations at ASRM 2023, in anticipation of a significant announcement
Presagen’s AI-based fertility product, Life Whisperer, will take the spotlight at the prestigious American Society for Reproductive Medicine (ASRM) 2023 conference in New Orleans this month, featuring in four oral presentations. Among these, two presentations stem from independent studies by the global fertility group, IVI-RMA, which operates across 70 fertility centers in 9 countries. The other two presentations showcase international clinical studies conducted across the USA and Europe, notably involving US Fertility and Ovation Fertility, which now combined, represent the largest fertility network in the USA, encompassing over 100 locations.
These studies provide further clinical evidence of Life Whisperer’s benefits regarding IVF and fertility treatment. Life Whisperer comprises a non-invasive, rapid, cost-effective, and objective AI which evaluates an embryo's morphological quality and its likelihood of being genetically normal (euploid). Life Whisperer has demonstrated a reduction in time-to-pregnancy compared to conventional manual morphological grading, ultimately improving success rates. With the aim of reducing costs and enhancing IVF outcomes for patients globally, Life Whisperer is currently available for sale in 47 countries worldwide*.
For the first time, Life Whisperer will also be exhibiting at ASRM with its largest presence yet, in anticipation of a major public announcement that will be made at the event.
Presagen’s CEO, Dr. Michelle Perugini, expressed her excitement, stating, "We are thrilled to unveil a major announcement at this year's ASRM, where we will also have a substantial scientific presence. The US is a pivotal market in our Life Whisperer strategy, and we eagerly anticipate sharing the latest AI advancements that support IVF treatments with the local IVF industry. Additionally, we look forward to forging new partnerships and collaborations for future product developments, including AI assessment of oocytes, or female eggs, and endometrial receptivity assessment via ultrasound."
* Life Whisperer Viability is not available in the USA.
Development of an automated system for morphological classification of embryos using image-based artificial intelligence
By Presagen/Life Whisperer (Australia, USA), USF-Ovation Fertility (USA), Texas Fertility Centre (USA), IVIRMA/IVI Foundation (EU) (oral presentation)
Objective: To develop an image-based artificial intelligence (AI) algorithm for automated embryo classification.
Presenting Author: Dr Jonathan Hall
Development of a non-invasive artificial intelligence algorithm for identification of euploid embryos with high morphological quality during IVF
By USF-Ovation Fertility (USA), Texas Fertility Centre (USA), Presagen/Life Whisperer (Australia, USA), IVF Florida (USA), IVIRMA/IVI Foundation (EU) (oral presentation)
Objective: To develop an image-based artificial intelligence (AI) algorithm for combined morphological and genetic assessment of embryo quality.
Presenting Author: Dr Matthew “Tex” VerMilyea
Simulated cohort analyses showed that an Automatic AI score reduced the number of cycles needed to achieve live birth and increased the first-cycle success rates
By IVIRMA Global Research Alliance (EU) (oral presentation, independent study)
Objective: To determine if a non-invasive AI algorithm based on deep learning improves selection of embryos leading to pregnancy and live birth.
Presenting Author: Carla Giménez-Rodríguez
Applying Artificial Intelligence to embryos: Can a deep learning algorithm predict the chromosomal status of an embryo?
By IVIRMA Global Research Alliance (EU) (oral presentation, independent study)
Objective: To determine if a non-invasive AI algorithm for evaluating the likelihood of embryo euploidy (genetic AI) is capable of identifying a genetically normal (euploid) embryo.
Presenting Author: Carla Giménez-Rodríguez
Life Whisperer
Life Whisperer is a world-leader in the application of AI in IVF. The Life Whisperer Viability and Genetics AI-based embryo assessment tools are the first to be commercialized in a series of applications that encompass the complete IVF journey. Life Whisperer aims to improve IVF success rates at every point and, as a result, reduce time-to-pregnancy, making IVF more affordable and accessible to patients globally. Life Whisperer is being used in IVF clinics around the world.
Presagen
Presagen is an AI healthcare company that is changing the way clinics, patients, and medical data from around the world are connected through AI. Its platform, The Social Network for Healthcare, connects clinics and patients globally, and enables collaboration and data sharing to create scalable AI healthcare products that are affordable and accessible for all. The decentralized network democratizes the creation of AI products, promotes collaboration through incentives, and protects data privacy and ownership.
With a focus on improving Women’s Health outcomes globally, Presagen’s first product, Life Whisperer, is being used by IVF clinics globally to improve pregnancy outcomes for couples struggling with fertility. With a vision of creating the largest network of clinics, patients, and medical data from around the world, Presagen is driving the future of AI Enhanced Healthcare.